Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:363 |
Name | uterine cancer |
Definition | A female reproductive organ cancer that is located_in the uterus. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4363 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ERBB2 pos PIK3CA act mut | Taselisib | uterine cancer | sensitive | detail... |
PIK3CA I391M | Sirolimus | uterine cancer | predicted - sensitive | detail... |
Unknown unknown | Pamiparib + Tislelizumab | uterine cancer | not applicable | detail... |
ERBB2 amp | Pertuzumab + Trastuzumab | uterine cancer | no benefit | detail... |
ERBB2 over exp | Pertuzumab + Trastuzumab | uterine cancer | no benefit | detail... |
FGFR2 amp | Debio 1347 | uterine cancer | predicted - sensitive | detail... |
PIK3CA mutant | Copanlisib | uterine cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Recruiting | USA | 0 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Recruiting | USA | 0 |
NCT02646319 | Phase I | Nab-Rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
NCT02874430 | Phase II | Doxycycline + Metformin | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | Recruiting | USA | 0 |
NCT03206177 | Phase I | Carboplatin + Galunisertib + Paclitaxel | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | Recruiting | USA | 0 |
NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Recruiting | USA | 1 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Recruiting | USA | 3 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Recruiting | USA | CAN | 0 |